Loading...
Printed on 7/19/2026
For informational purposes only. This is not medical advice.
HOMA-Beta (HOMA-%B) estimates pancreatic beta-cell function from fasting insulin and fasting glucose. It is often interpreted together with HOMA-IR and other glycemic markers to understand insulin secretion relative to insulin resistance.
Formula: HOMA-Beta = (360 x Fasting Insulin [uIU/mL]) / (Fasting Glucose [mg/dL] - 63)
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Input fasting serum insulin (mcU/mL) and fasting plasma glucose (mg/dL), drawn after an 8–12 hour fast. The mg/dL glucose value is used directly. If your lab reports glucose in mmol/L, multiply by 18.0 to convert to mg/dL before entering. Glucose values below 64 mg/dL (3.6 mmol/L) cannot be used because the denominator of the formula approaches zero and the result becomes mathematically unreliable.
The tool applies HOMA-β = (360 × fasting insulin [mcU/mL]) / (fasting glucose [mg/dL] − 63), which is the mg/dL adaptation of the original Matthews et al. formula. This equation models basal beta-cell insulin secretion relative to the glucose stimulus under fasting steady-state conditions. The constant 360 comes from the original model's 20 × 18 conversion (mmol/L to mg/dL).
HOMA-β is expressed as a percentage where 100% represents the estimated beta-cell function of a healthy non-diabetic adult. Values of 80–120% are considered normal. Values below 80% suggest beta-cell decline; below 40% is consistent with significant secretory loss, typical of established T2DM at diagnosis. Values above 120% can reflect compensatory hypersecretion in early insulin resistance before glucose control deteriorates.
Diabetologists, endocrinologists
The UKPDS demonstrated that T2DM patients have already lost approximately 50% of their beta-cell function by the time of diagnosis, and function continues to decline ~4% per year thereafter. Serial HOMA-β measurements over months and years document this progressive decline, helping guide the timing of therapy intensification (adding GLP-1 agonist, SGLT2 inhibitor, or insulin).
Endocrinologists, diabetologists
Latent Autoimmune Diabetes in Adults (LADA) is often misclassified as T2DM. LADA patients characteristically have low HOMA-β combined with positive anti-GAD antibodies (anti-glutamic acid decarboxylase). A HOMA-β below 25–30% in a patient thought to have T2DM should prompt testing for GAD antibodies to rule out LADA and guide appropriate treatment (insulin rather than sulphonylureas).
Endocrinologists, clinical pharmacologists
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are thought to exert beta-cell protective and possibly regenerative effects beyond glucose lowering. Serial HOMA-β monitoring before and during GLP-1 therapy provides objective evidence of whether beta-cell secretory function improves with treatment, informing therapy continuation decisions.
Primary care, internists, diabetologists
Very low HOMA-β (below 25–30%) in a T2DM patient is associated with near-complete beta-cell failure and predicts the need for insulin therapy. When oral agents are failing and HOMA-β is very low, this supports early insulin initiation rather than continued escalation of oral diabetes medications that depend on some residual beta-cell function (especially sulfonylureas).
Clinical researchers, diabetes investigators
Combination of HOMA-β with HOMA-IR creates a two-axis metabolic phenotype for new-onset diabetes: high HOMA-IR / normal HOMA-β (predominant insulin resistance), normal HOMA-IR / low HOMA-β (predominant secretory failure), or mixed. This phenotypic classification is used in research to identify patient subgroups most likely to respond to specific treatment approaches.
HOMA-β using the mg/dL formula becomes unreliable when fasting glucose exceeds approximately 450 mg/dL (equivalent to 25 mmol/L in the original formula), because the denominator grows proportionally with glucose, compressing the result. In severe hyperglycemia, HOMA-β underestimates true beta-cell function. Interpret with caution in patients with glucose above 300–350 mg/dL.
The landmark UKPDS study demonstrated that at the time of T2DM diagnosis, patients have already lost approximately 50% of their beta-cell secretory capacity. This loss begins years before diagnosis during the prediabetes phase. HOMA-β typically falls from ~100% in healthy adults to 40–60% at T2DM diagnosis and continues declining ~4% per year thereafter.
HOMA-β and HOMA-IR together characterize both sides of the insulin axis: secretion (HOMA-β) and action (HOMA-IR). A patient with high HOMA-IR but normal HOMA-β has compensated insulin resistance (early metabolic syndrome). A patient with low HOMA-β and normal HOMA-IR has primarily secretory failure (LADA, late T2DM). Both together provide a more complete metabolic phenotype than either alone.
Multiple clinical trials of semaglutide and liraglutide have demonstrated increases in HOMA-β over 6–24 months of treatment, suggesting these agents preserve or restore some beta-cell secretory capacity. The mechanism may involve reduction in glucotoxicity, lipotoxicity, and direct beta-cell trophic effects mediated by GLP-1 receptors on islet cells.
LADA accounts for 5–10% of patients initially diagnosed with T2DM. These patients characteristically have HOMA-β below 25–30% with positive anti-GAD antibodies, despite an apparently T2DM clinical presentation. Low HOMA-β in a lean-to-normal BMI patient with poor response to oral agents should always prompt anti-GAD antibody testing.
In early insulin resistance (high HOMA-IR) with normal glucose, HOMA-β is often elevated above 100% — reflecting compensatory hypersecretion by a stressed but functional pancreas. This should not be interpreted as 'good' — it represents the overworked pancreas response to insulin resistance that precedes eventual beta-cell exhaustion and T2DM development.
East Asian populations have been shown to have lower beta-cell secretory capacity and lower HOMA-β at baseline compared to European populations at similar BMI and glucose levels. This explains why Asian individuals develop T2DM at lower BMI thresholds. Population-appropriate reference ranges should be used when available, particularly for Asian patient populations.
HOMA-β requires endogenous insulin measurement. Patients already receiving insulin therapy (for T1DM or advanced T2DM) cannot be assessed because the assay cannot separate endogenous from exogenous insulin, and injected insulin creates artifactually elevated insulin readings. Only patients on oral medications or no diabetes medications can be evaluated.
A single HOMA-β measurement provides a snapshot; serial measurements over 6–12 month intervals during T2DM management create a trend that reveals disease progression rate. Stable or improving HOMA-β on a GLP-1 agonist versus declining HOMA-β on metformin alone can objectively guide therapy optimization decisions.
HOMA-β was introduced by Matthews et al. (Diabetologia 1985) alongside HOMA-IR as part of the Homeostatic Model Assessment framework. It estimates relative beta-cell secretion under fasting conditions. The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated progressive beta-cell decline in T2DM patients, establishing the clinical context for HOMA-β monitoring. HOMA-β was validated against intravenous glucose tolerance test (IVGTT)-based measurements of first-phase insulin secretion (Turner et al., Diabetologia 1979). The GLP-1 agonist effects on HOMA-β are documented in semaglutide and liraglutide trials (SUSTAIN and LEADER trials, N Engl J Med 2016–2017).
HOMA-Beta estimates beta-cell function; lower values may suggest reduced insulin secretory reserve, while higher values can reflect compensatory hyperinsulinemia.
Use HOMA-Beta when evaluating fasting insulin secretion patterns in prediabetes and type 2 diabetes risk assessment.
HOMA-Beta is a fasting-model estimate and is affected by assay variability and population differences. It should not be used alone for diagnosis or treatment decisions.
For related assessments, see HOMA-IR, QUICKI and HbA1c Converter.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Estimate insulin resistance using fasting glucose and fasting insulin with the HOMA-IR equation.
OpenEndocrinologyEstimate insulin sensitivity using fasting glucose and fasting insulin with the QUICKI formula.
OpenEndocrinologyConvert HbA1c to estimated average glucose (eAG): 6%=126 mg/dL, 7%=154, 8%=183, 9%=212. ADA 2026 target <7% for most adults with diabetes. Shows both mg/dL and mmol/L.
Open